Media stories about FibroGen (NASDAQ:FGEN) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. FibroGen earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.4668024112271 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Analysts Predict 22% Upside For PBE – Nasdaq (nasdaq.com)
- Insider Buying: FibroGen, Inc (FGEN) Director Acquires 3,500 Shares of Stock (americanbankingnews.com)
- FibroGen is Now Oversold (FGEN) (nasdaq.com)
- FibroGen (FGEN) Cut to “Sell” at ValuEngine (americanbankingnews.com)
- Jorma Routti Sells 12,000 Shares of FibroGen, Inc (FGEN) Stock (americanbankingnews.com)
Several research analysts have recently weighed in on the company. BidaskClub downgraded FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday. ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Mizuho reiterated a “hold” rating and set a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 price target on shares of FibroGen in a research note on Thursday, September 14th. Finally, Jefferies Group reiterated a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $65.67.
In other FibroGen news, Director Thomas F. Kearns, Jr. sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $45.22, for a total value of $813,960.00. Following the completion of the transaction, the director now owns 156,564 shares in the company, valued at approximately $7,079,824.08. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas B. Neff sold 18,900 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $46.60, for a total value of $880,740.00. Following the completion of the transaction, the chief executive officer now owns 3,109,555 shares of the company’s stock, valued at approximately $144,905,263. The disclosure for this sale can be found here. In the last 90 days, insiders sold 399,982 shares of company stock valued at $21,250,362. 13.60% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect FibroGen (FGEN) Share Price” was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3080731/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-fibrogen-fgen-share-price.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.